Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Defining the protective antibody response for HIV-1.

Mascola JR.

Curr Mol Med. 2003 May;3(3):209-16. Review.

PMID:
12699358
2.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL.

J Virol. 2003 Oct;77(19):10348-56.

3.

Neutralizing antibodies against HIV -- back in the major leagues?

Ferrantelli F, Ruprecht RM.

Curr Opin Immunol. 2002 Aug;14(4):495-502. Review.

PMID:
12088685
4.
5.

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM.

Vaccine. 2002 May 6;20(15):1956-60. Review.

PMID:
11983253
6.

Passive immunization as tool to identify protective HIV-1 Env epitopes.

Kramer VG, Siddappa NB, Ruprecht RM.

Curr HIV Res. 2007 Nov;5(6):642-55. Review.

PMID:
18045119
7.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
8.

Antibodies: can they protect against HIV infection?

Mc Cann CM, Song RJ, Ruprecht RM.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):95-111. Review.

PMID:
15975016
9.

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA.

Nat Med. 1997 Dec;3(12):1389-93.

PMID:
9396610
10.

Role of neutralizing antibodies in protective immunity against HIV.

Srivastava IK, Ulmer JB, Barnett SW.

Hum Vaccin. 2005 Mar-Apr;1(2):45-60. Epub 2005 Mar 17. Review.

PMID:
17038830
11.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

Srivastava IK, Ulmer JB, Barnett SW.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S33-52. Review.

PMID:
15285704
12.

Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.

Cavacini LA, Duval M, Patil A, Wood C, Mayer KH, Ruprecht RM, Posner MR.

J Med Virol. 2005 Jun;76(2):146-52.

PMID:
15834877
13.

Bioorganic approaches towards HIV vaccine design.

Wang LX.

Curr Pharm Des. 2003;9(22):1771-87. Review.

PMID:
12871196
14.

Biological considerations in the development of a human immunodeficiency virus vaccine.

Nathanson N, Mathieson BJ.

J Infect Dis. 2000 Aug;182(2):579-89. Epub 2000 Jul 28. Review.

PMID:
10915092
15.

Correlates of protective immunity against HIV-1 infection in immunized chimpanzees.

Murthy KK, Cobb EK, Rouse SR, Lunceford SM, Johnson DE, Galvan AR.

Immunol Lett. 1996 Jun;51(1-2):121-4. Review.

PMID:
8811355
16.
17.

Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M.

J Med Virol. 2004 Jul;73(3):368-77.

PMID:
15170630
18.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

19.

HIV-1: the confounding variables of virus neutralization.

Nara PL, Lin G.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):157-70. Review.

PMID:
15975021
20.

Development of prophylactic AIDS vaccines: the current state of affairs.

Hanke T.

Curr Opin Mol Ther. 2003 Feb;5(1):25-32. Review.

PMID:
12669467

Supplemental Content

Support Center